title: A brief exposure to tryptase or thrombin potentiates fibrocyte differentiation in the presence of serum or serum amyloid p.
abstract: A key question in both wound healing and fibrosis is the trigger for the initial formation of scar tissue. To help form scar tissue, circulating monocytes enter the tissue and differentiate into fibroblast-like cells called fibrocytes, but fibrocyte differentiation is strongly inhibited by the plasma protein serum amyloid P (SAP), and healthy tissues contain very few fibrocytes. In wounds and fibrotic lesions, mast cells degranulate to release tryptase, and thrombin mediates blood clotting in early wounds. Tryptase and thrombin are upregulated in wound healing and fibrotic lesions, and inhibition of these proteases attenuates fibrosis. We report that tryptase and thrombin potentiate human fibrocyte differentiation at biologically relevant concentrations and exposure times, even in the presence of concentrations of serum and SAP that normally completely inhibit fibrocyte differentiation. Fibrocyte potentiation by thrombin and tryptase is mediated by protease-activated receptors 1 and 2, respectively. Together, these results suggest that tryptase and thrombin may be an initial trigger to override SAP inhibition of fibrocyte differentiation to initiate scar tissue formation.
authors.affiliation: Department of Biology, Texas A&M University, College Station, TX 77843-3474.
authors.forename: Michael J V
authors.initials: MJ
authors.lastname: White
authors.affiliation: Department of Biology, Texas A&M University, College Station, TX 77843-3474.
authors.forename: Elkin
authors.initials: E
authors.lastname: Galvis-Carvajal
authors.affiliation: Department of Biology, Texas A&M University, College Station, TX 77843-3474 rgomer@tamu.edu.
authors.forename: Richard H
authors.initials: RH
authors.lastname: Gomer
mesh_terms: D000418:Albumins / Q000378:metabolism / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects / Q000276:immunology; D002465:Cell Movement; D002478:Cells, Cultured; D002921:Cicatrix / Q000473:pathology*; D005347:Fibroblasts / Q000166:cytology; D005355:Fibrosis / Q000473:pathology*; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D007783:Lactones / Q000494:pharmacology; D007963:Leukocytes, Mononuclear; D009000:Monocytes / Q000166:cytology; D011725:Pyridines / Q000494:pharmacology; D011758:Pyrroles / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology; D044463:Receptor, PAR-1 / Q000096:biosynthesis / Q000378:metabolism; D044464:Receptor, PAR-2 / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism; D000683:Serum Amyloid P-Component / Q000378:metabolism*; D015398:Signal Transduction / Q000276:immunology; D013917:Thrombin / Q000378:metabolism / Q000494:pharmacology*; D014357:Trypsin / Q000494:pharmacology; D053802:Tryptases / Q000378:metabolism / Q000494:pharmacology*; D014945:Wound Healing; D010975:Platelet Aggregation Inhibitors
chemical_list: D000418:Albumins; D007783:Lactones; C415424:N3-cyclopropyl-7-((4-(1-methylethyl)phenyl)methyl)-7H-pyrrolo(3, 2-f)quinazoline-1,3-diamine; D011725:Pyridines; D011758:Pyrroles; D011799:Quinazolines; D044463:Receptor, PAR-1; D044464:Receptor, PAR-2; D000683:Serum Amyloid P-Component; D007371:Interferon-gamma; D014357:Trypsin; D013917:Thrombin; D053802:Tryptases; C530299:vorapaxar; D010975:Platelet Aggregation Inhibitors